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Abstract
Background: Coenzyme Q10 (CoQ10) and its analogs are used therapeutically by virtue of their functions as electron carriers,
antioxidant compounds, or both. However, published studies suggest that different ubiquinone analogs may produce
divergent effects on oxidative phosphorylation and oxidative stress.
Methodology/Principal Findings: To test these concepts, we have evaluated the effects of CoQ10, coenzyme Q2 (CoQ2),
idebenone, and vitamin C on bioenergetics and oxidative stress in human skin fibroblasts with primary CoQ10 deficiency. A
final concentration of 5 mM of each compound was chosen to approximate the plasma concentration of CoQ10 of patients
treated with oral ubiquinone. CoQ10 supplementation for one week but not for 24 hours doubled ATP levels and ATP/ADP
ratio in CoQ10 deficient fibroblasts therein normalizing the bioenergetics status of the cells. Other compounds did not affect
cellular bioenergetics. In COQ2 mutant fibroblasts, increased superoxide anion production and oxidative stress-induced cell
death were normalized by all supplements.
Conclusions/Significance: These results indicate that: 1) pharmacokinetics of CoQ10 in reaching the mitochondrial
respiratory chain is delayed; 2) short-tail ubiquinone analogs cannot replace CoQ10 in the mitochondrial respiratory chain
under conditions of CoQ10 deficiency; and 3) oxidative stress and cell death can be counteracted by administration of
lipophilic or hydrophilic antioxidants. The results of our in vitro experiments suggest that primary CoQ10 deficiencies should
be treated with CoQ10 supplementation but not with short-tail ubiquinone analogs, such as idebenone or CoQ2.
Complementary administration of antioxidants with high bioavailability should be considered if oxidative stress is present.
Citation: Lo´pez LC, Quinzii CM, Area E, Naini A, Rahman S, et al. (2010) Treatment of CoQ10 Deficient Fibroblasts with Ubiquinone, CoQ Analogs, and Vitamin C:
Time- and Compound-Dependent Effects. PLoS ONE 5(7): e11897. doi:10.1371/journal.pone.0011897
Editor: Antoni L. Andreu, Hospital Vall d’Hebron, Spain
Received May 13, 2010; Accepted June 30, 2010; Published July 30, 2010
Copyright:  2010 Lo´pez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by U.S. National Institutes of Health (NIH) grants HD32062 and NS11766, by grants from the Muscular Dystrophy Association
(MDA), and by the Marriott Mitochondrial Disorders Clinical Research Fund (MMDCRF). LCL was supported by a post-doctoral fellowship from the Ministerio de
Educacio´n y Ciencia, Spain. CMQ is supported by the MDA. LS is supported by Telethon grant GGP09207. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Santhera Pharmaceuticals (Switzerland) Ltd supplied idebenone for this study. In addition, Dr. Hirano has a research contract with
Santhera for a clinical trial of idebenone for a mitochondrial disease (Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like episode [MELAS]). Dr.
Hirano receives no salary support from Santhera. Other than supplying idebenone, Santhera was not involved in the research described in this manuscript. The
work of Dr. Hirano and colleagues was performed independently of Santhera. In fact, the results of this study may be viewed as negative for Santhera, because the
findings suggest that idebenone cannot replace coenzyme Q10 in the mitochondrial respiratory chain.
* E-mail: mh29@columbia.edu
. These authors contributed equally to this work.
Introduction
Coenzyme Q10 (CoQ10; ubiquinone) and its analogs have been
evaluated as antioxidant agents and enhancers of mitochondrial
functions in patients with mitochondrial disorders and clinical
trials of neurodegenerative diseases including Parkinson disease,
amyotrophic lateral sclerosis, Huntington disease, Friedreich
ataxia, and Alzheimer’s disease with modest or no objective
benefits [1–6]. The use of CoQ10 therapy and its analogs in
primary CoQ10 deficiency, an autosomal recessive syndrome due
to defects of ubiquinone biosynthesis, could provide valuable data
to evaluate the effectiveness of these compounds in restoring
respiratory chain activities and preventing oxidative stress. The
disorder manifests clinically with four major phenotypes: 1) an
encephalomyopathy with brain involvement and recurrent
myoglobinuria [7]; 2) an infantile multisystem disorder with
encephalopathy usually associated with nephropathy and variable
involvement of other organs [8,9]; 3) ataxic syndrome with
cerebellar atrophy [10,11]; and 4) an isolated myopathy [12,13].
Molecular defects in genes encoding CoQ10 biosynthetic
proteins have been reported in 18 patients. Four patients improved
with CoQ10 supplementation [9,14–17], five died before or during
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the treatment, and 9 had no definite response [14,15,18–22]; it is
therefore difficult to reach definitive conclusions about the
effectiveness of CoQ10 supplementation in primary CoQ10
deficiencies. To better understand the pathogenesis of CoQ10
deficiency, we have characterized the bioenergetics and oxidative
stress in PDSS2 and COQ2 mutant fibroblasts, and have
demonstrated that severe CoQ10 deficiency caused marked defects
of ATP synthesis without oxidative stress whereas milder CoQ10
deficiency produced reactive oxygen species (ROS) and oxidation
of proteins and lipids [23]. Here, we evaluate the in vitro effects of
CoQ10 supplementation on the bioenergetics and oxidative stress
status of CoQ10 deficient fibroblasts with mutations in PDSS2,
COQ2, and COQ9 (Fig. 1). In addition, because CoQ10 analogs and
vitamin C are being used in clinical trials based on their
antioxidant properties, we concurrently evaluated the effect of
CoQ2, idebenone, and vitamin C.
Results
Cellular CoQ10 levels after treatment with compounds for
24 hours
Fibroblasts from the four patients with different molecular
defects in the CoQ10 biosynthetic pathway used in this study
showed significantly decreased levels of CoQ10 relative to controls
(P,0.001) (Fig. 2). When control and patients’ cells were treated
for 24 h with 5 mM of CoQ10, cellular levels of ubiquinone
increased significantly in all cells (P,0.001), resulting in values 20–
85-fold higher than in control cells (Fig. 2). When the cells were
treated with idebenone, CoQ2, or vitamin C, cellular levels of
CoQ10 remained unchanged (Fig. 2).
Bioenergetic status: 24 hours versus 1 week of treatment
The four CoQ10 deficient fibroblasts showed significant
decreases in cellular ATP levels (P,0.001) (Fig. 3A) and ATP/
ADP ratios (P,0.001) (Fig. 3B). Treatment with 5 mM CoQ10,
idebenone, CoQ2, or vitamin C for 24 h did not increase ATP
levels or ATP/ADP ratios. However, treatment with 5 mM CoQ10
for 1 week increased significantly levels of cellular ATP in P1
(P,0.001), P2 (P,0.001), and P4 (P,0.05) to normal levels
(Fig. 4A). At the same time, ATP/ADP ratios were significantly
increased in P1 (P,0.01), P2 (P,0.01), and P4 (P,0.05) (Fig. 4B)
thus bringing to normal the bioenergetics status of the cells. In
contrast, idebenone, CoQ2, and vitamin C treatment failed to alter
ATP levels or ATP/ADP ratios (Fig. 4).
The effect of compound administration on superoxide
anion levels: 24 hours versus 1 week of treatment
After incubation for 24 h in galactose medium supplemented
with dialyzed FBS, P3 cells showed increased MitoSOX Red stain
indicating elevated levels of superoxide anions (P,0.001) (Fig. 5A).
Under the same culture conditions, the other three CoQ10
deficient fibroblasts did not show any significant changes in
MitoSOX stain. After 24 h of treatment with CoQ10, idebenone,
CoQ2, or vitamin C, superoxide anion levels decreased signifi-
cantly in P3 cells (P,0.01) (Fig. 5A). Cells from controls and from
the three other patients did not show significant changes in
MitoSOX stain after 24 hours of treatment with any of the four
compounds; however, there was a trend towards increased
superoxide anions in P4 cells treated with CoQ2 for 24 h (Fig. 5A).
After one week of incubation in galactose medium plus dialyzed
FBS, P2 and P3 cells showed increased MitoSOX Red staining
(Fig. 5B). After 1 week of treatment with CoQ10, idebenone,
CoQ2, or vitamin C, superoxide anion levels were decreased
significantly in both P2 and P3 cells (P,0.001) (Fig. 5B).
The effect of compound administration on cell death:
24 hours versus 1 week treatment
In adherent cells, cell death was significantly higher in untreated
P2 and P3 cells than in control cells (P,0.05 and P,0.01,
respectively) (Fig. 6A). Cell death was significantly reduced in both
P2 and P3 treated for 24 h with CoQ10 (P,0.01) or idebenone
(P,0.05). Vitamin C also reduced cell death in P3 cells (P,0.05)
(Fig. 6A). Control, P1, and P4 cells showed similar proportions of
dead cells with and without treatment (Fig. 6A).
Untreated P2 and P3 cells also showed significantly higher cell
death than controls when incubated for 1 week in galactose
medium supplemented with dialyzed FBS (P,0.01 and P,0.001,
respectively) (Fig. 6B). Cell death was reduced in P2 cells by 24 h
treatment with CoQ10 (P,0.05), idebenone (P,0.05), CoQ2
(P,0.01), or vitamin C (P,0.05); and in P2 cells by one week
treatment with CoQ10 (P,0.001), idebenone (P,0.05), CoQ2
(P,0.001), or vitamin C (P,0.001) (Fig. 6B). While the P3 cell
death levels were significantly reduced by treatment with
idebenone for 1 week (P,0.05), they were still significantly higher
than those of control cells (P,0.001) (Fig. 6B).
Because we observed abundant floating COQ2 mutant cells
cultured in galactose medium with dialyzed FBS, we performed
Trypan blue staining of P2 cells and found that 15% of the cells
were dead after 24 h and 63% were dead after 1 week.
Percentages of floating dead cells were significantly decreased
after one week of treatment with CoQ10 (36% dead cells), CoQ2
(45% dead cells), or idebenone (43% dead cells).
Discussion
Over the last 4 years, studies of CoQ10 deficient patients have
focused on two major issues: identifying the molecular genetic
basis of ubiquinone deficiencies and characterizing pathogenic
mechanisms [24]. We identified the two first mutations in genes
encoding proteins required for CoQ10 biosynthesis, COQ2 [17]
and PDSS2 [20], in patients with primary CoQ10 deficiency. Our
studies of cultured fibroblasts from these patients revealed that
both CoQ10 biosynthetic disorders caused bioenergetic defects, but
only COQ2 mutant fibroblasts showed increased ROS production
and signs of oxidative stress [23]. In the present study, we have
evaluated the in vitro efficacy of CoQ10 supplementation in
normalizing the bioenergetic status and the oxidative balance in
fibroblasts of CoQ10 deficient patients harboring mutations in
PDSS2, COQ2, and COQ9 [14,17,18,20,23]. We chose a final
concentration of 5 mM CoQ10 because this is the approximate
concentration reached in the plasma of patients treated with oral
supplementation of CoQ10 [3,6,25–27]. We have also evaluated
the efficacy of short-tail ubiquinone analogs (idebenone and
CoQ2), which are less lipophilic, and vitamin C, a well-known
hydrophilic antioxidant. It is noteworthy that 5 mM concentrations
of ubiquinone analogs exceed the EC50 of idebenone (,0.4–
0.5 mM) and CoQ2 (,0.03 mM) in cultured fibroblasts under
oxidative stress [28,29].
After 24 h of 5 mM CoQ10 supplementation, cellular CoQ10
levels increased dramatically. The magnitudes of the increases
were independent of the molecular defects of the cells since both
control and patients’ fibroblasts showed similar degrees of CoQ10
uptake. However, after 24 h of CoQ10 treatment, none of the cell
lines showed significant improvement in ATP levels or in ATP/
ADP ratios, which are markers of respiratory chain function. In
contrast to our results, Lo´pez-Martı´n and colleagues [30] noted
normalization of mitochondrial complexes I+III and II+III
activities in COQ2 mutant fibroblasts after 24 h of 10 mM
CoQ10 supplementation. Paradoxically, however, the same
Treatment of CoQ10 Deficiency
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authors using the same COQ2 mutant cells and other genetically
undefined CoQ10 deficient fibroblasts found that the activities of
complex II+III activities increased only slightly and remained
below control values after 72 hours of 100 mM CoQ10 supple-
mentation [31]. This discrepancy may be due to the fact that in
the second study, but not in the first, respiratory chain enzyme
activities were normalized to the activity of citrate synthase [31], a
marker of mitochondrial mass [32]. In another study, embryonic
cells from COQ7 knockout mice treated with 25 mM of water-
soluble CoQ10 for 5 h only showed slight increase of ATP [33].
The negligible effects of CoQ10 supplementation on the
bioenergetic status of CoQ10 deficient cells can be explained by
the strong lipophilic nature of CoQ10, which accumulates in
membranes reaching saturated concentrations [34,35]. Thus,
exogenous CoQ10 is mainly distributed in lysosomes, endoplasmic
reticulum, and plasma membrane and only a small proportion
(,11%) reaches the mitochondria [36,37]. In addition, much of
the CoQ10 in mitochondria is likely to be trapped in the outer
membrane, not available to the respiratory chain, which is located
in the mitochondrial inner membrane [38].
Because 5 mM CoQ10 did not increase the ATP levels after 24 h
of supplementation, we tried two other strategies: 1) increasing the
duration of CoQ10 supplementation to 1 week; and 2) using less-
lipophilic ubiquinone analogs. In marked contrast to treatment for
24 h of CoQ10, incubation of ubiquinone-deficient fibroblasts for 1
week with 5 mM CoQ10 increased ATP levels and ATP/ADP
ratios significantly, indicating normalization of the bioenergetic
status. Similar to these results, yeast coq mutants show inefficient
uptake of exogenous CoQ6 to the mitochondrial inner membrane,
which is reflected in a low succinate cytochrome c reductase
activity after 2–15 mM CoQ6 supplementation for 48 h [37,39].
The complete rescues of growth of the yeast coq mutants’
supplemented with 15 mM CoQ6 were only possible after 6–8 days
[37,39,40]. These results suggest that the pharmacokinetic
constraints of CoQ10 in reaching the mitochondrial respiratory
chain are key limiting factors in determining its efficacy in CoQ10
deficient patients. Furthermore, an in vivo study of PDSS2 mutant
mice treated for 4 months with 100 mg/kg body weight (b.w.)/day
or 200 mg/kg b.w./day of water-soluble CoQ10 showed that only
the highest dose of CoQ10 improved the renal function in these
CoQ deficient animals [41]. Thus, the dose of CoQ10 is another
important factor influencing the effectiveness of CoQ10 supple-
mentation in ubiquinone deficient patients. Nevertheless, the gold
standard to evaluate the effectiveness of CoQ10 treatment in
ubiquinone deficiency is in vivo measurements of mitochondrial
function, bioenergetics, and oxidative stress.
In contrast to CoQ10, short-tail ubiquinone analogs and
vitamin C failed to increase ATP levels and ATP/ADP ratio in
patients’ cells after both 24 h and 1 week treatment. These results
are in agreement with previous studies showing that hydrophilic
ubiquinone analogs (CoQ2 and idebenone) or mitochondrial-
targeted ubiquinone (MitoQ) are less efficient than hydrophobic
ubiquinone analogs in enhancing energy production by the
mitochondrial respiratory chain [42–44], since the specific effects
Figure 2. Cellular CoQ10 levels after 24 hours of treatment. Cultured skin fibroblasts from controls and CoQ10 deficiency patients were treated
with 5 mM CoQ10, idebenone, CoQ2 or vitamin C. After 24 hours, fibroblasts were collected and cellular CoQ10 were determined by EQ-HPLC. Results
are expressed as a mean 6 SD of three experiments. P1 =COQ9 mutant; P2 = COQ2 mutant; P3 = COQ2 mutant; P4 = PDSS2 mutant. ***P,0.001
compared with untreated control; ###P,0.001 compared with untreated P1; +++P,0.001 compared with untreated P2; www P,0.001 compared
with untreated P3; VVV P,0.001 compared with untreated P4.
doi:10.1371/journal.pone.0011897.g002
Figure 1. CoQ10 biosynthesis pathway. CoQ10 is composed of a benzoquinone and a decaprenyl side chain. PDSS2 is the second subunit of
decaprenyl diphosphate synthase, a heterotretameric enzyme that catalyzes the formation of the decaprenyl side chain. COQ2 or para-
hydroxybenzoate (PHB)-polyprenyl transferase catalyzes the condensation reaction of PHB and decaprenyl diphosphate. The function of COQ9 is still
unknown. The mutant fibroblasts used in this study harbor mutations in COQ9, p.244R.X (P1) [18], COQ2, p.197R.H, p.228N.S (P2) [14] and
p.297Y.C (P3) [17], and PDSS2, p.322Q.X, p.382S.L (P4) [20].
doi:10.1371/journal.pone.0011897.g001
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of ubiquinones depend on their interaction with hydrophilic and
hydrophobic (or physiological) binding sites [42,43]. Accordingly,
hydrophobic and hydrophilic ubiquinone analogs are not
interchangeable. Experience with two patients with CoQ10
deficiency and cerebellar ataxia due to ADCK3/CABC1 mutations
is relevant. Both patients were treated with CoQ10 (5–10 mg/kg/
b.w.) [21,45]. One patient, who also had exercise intolerance and
hyperlactatemia, improved after 3 months of treatment whereas
the other, who had only ataxia, did not benefit from 3 years of
therapy. The ataxia did not improve in either patient and for this
reason CoQ10 was replaced with low-dose idebenone in both
patients (5–10 mg/kg/b.w.). However, their symptoms worsened,
prompting reinstitution of CoQ10 therapy [21,45]. Based on our
in vitro results showing improvements of bioenergetics by
ubiquinone in CoQ10 deficient cells, we postulate that CoQ10
therapy improved the first patient’s exercise intolerance and may
have stabilized symptoms in the second patient because of
enhanced ATP production. The lack of improvement of
cerebellar symptoms may be due to poor transfer of CoQ10
across the blood brain barrier, irreversible structural alterations in
the cerebellum, or both factors [36], especially considering the
low dose used (5–10 mg/kg/b.w.). Our finding that high doses of
idebenone in vitro failed to increase ATP levels in CoQ10 deficient
fibroblasts or the low-dose used for therapy may explain
ineffectiveness of idebenone therapy compared to CoQ10
treatment in both patients.
Because oxidative stress is another important pathogenic factor
in CoQ10 deficiencies, we evaluated also the effect of CoQ10 and
three other antioxidants on superoxide anion production. After
both 24 h and after 1 week of treatment, we noted that all four
compounds significantly reduced MitoSox staining in P3 cells (the
cell line with the most prominent MitoSox fluorescence).
Reduction of superoxide anion levels correlated with decreased
cell death, suggesting that ROS generation and oxidative damage
are the main causes of death in COQ2 mutant fibroblasts. This
notion is supported by our observation that P3 COQ2 fibroblast
line had the highest levels of superoxide anion production and
protein oxidation and showed the most robust features of apoptosis
and the highest proportion of cell death [46]. In contrast to COQ2
mutant fibroblasts, COQ9 and PDSS2 mutant fibroblast do not
have increased ROS, a difference that may be related to the
disparate CoQ-dependent flow of electrons in the mitochondrial
respiratory chain in the different mutant cell lines. As we recently
reported, 10–15% residual CoQ10 are not associated with
significant ROS production, whereas 30–50% residual CoQ10 is
accompanied by increased ROS production and cell death
[23,46]. Interestingly, there was a trend towards increased ROS
production in P4 cells supplemented with CoQ2 for 24 h and in P1
cells supplemented with idebenone for 1 week. In contrast,
idebenone decreased ROS levels in the other 3 cell lines after one
week of treatment. Our data suggest that these compounds may
have pro-oxidant and anti-oxidant properties under certain in vitro
Figure 3. Bioenergetic status of cells after 24 hours of treatment. Cultured skin fibroblasts from controls and CoQ10 deficient patients were
treated with 5 mM CoQ10, idebenone, CoQ2, or vitamin C. After 24 h, fibroblasts were collected and cellular ATP and ADP were determined by UV-
HPLC. Data are represented as nmol of ATP/mg prot (A) and ATP/ADP ratio (B). Results are expressed as mean6 SD of three experiments. P1 = COQ9
mutant; P2 = COQ2 mutant; P3 = COQ2 mutant; P4 = PDSS2 mutant. ***P,0.001 compared with untreated control.
doi:10.1371/journal.pone.0011897.g003
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conditions [47] and confirm in cultured fibroblasts observations
previously reported in isolated mitochondria [48].
In summary, our in vitro study tackles important issues regarding
treatment of CoQ10 deficiency and, more in general, of
mitochondrial diseases. First, the prolonged pharmacokinetics of
CoQ10 to reach the mitochondrial respiratory chain is critical to
the restoration of energy status of human CoQ10 deficient cells.
This may explain the delayed clinical response of CoQ10
deficiency patients to oral supplementation with CoQ10 [16] and
suggest that high doses of CoQ10 are needed. Second, short tail
ubiquinone analogs cannot substitute for CoQ10 in the mitochon-
drial respiratory chain of human CoQ10 deficient cells revealing
the importance of the decaprenyl tail. Third, oxidative stress and
cell death can be attenuated by the administration of lipophilic
and hydrophilic antioxidants.
Thus, our results confirm that in CoQ10 deficient patients: (i)
early treatment based on early diagnosis is critical to maximize the
efficacy of ubiquinone supplementation; (ii) short-tail ubiquinone
analogs (i.e. idebenone or CoQ2) are not suitable substitutes for
CoQ10; and (III) complementary administration of antioxidants
with high bioavailability may be helpful in CoQ10 deficiency
patients. Further studies on the pathogenesis of CoQ10 deficiency
in patients with different molecular defects and in animal models
will lead to more rational and improved therapies.
Materials and Methods
Ethics Statement
Skin biopsies, to generate cultured fibroblasts, were performed
after obtaining written informed parental consents under study
protocols approved by the Institutional Review Boards of the
Columbia University Medical Center, University of Padova, and
Charite´ University Hospital as well as Local Research Ethics
committees of Great Ormond Street Hospital for Children NHS
Trust and Institute of Child Health. The informed consents and
clinical studies were in compliance with the principles expressed in
the Declaration of Helsinki.
Cells culture and treatment
All experiments were performed in human skin fibroblasts from
5 controls and 4 CoQ10 deficient patients (Fig. 1): P1 with a
homozygous mutation in COQ9 (p.R244X) [18]; P2 with
compound heterozygous mutations in COQ2 (p.R197H and
p.N228S) [14]; P3 with a homozygous mutation in COQ2
(p.Y297C) [17]; and P4 with compound heterozygous mutations
in PDSS2 (p.Q322X and p.S382L) [20]. Cells were grown in
RPMI high-glucose medium supplemented with 10% fetal bovine
serum, 5 ml MEM non-essential amino acids, 1 ml fungizone, and
5 ml penicillin-streptomycin until 80% confluent.
Figure 4. Bioenergetic status of cells after 1 week of treatment. Cultured skin fibroblasts from controls and CoQ10 deficient patients were
treated with 5 mM CoQ10, idebenone, CoQ2, or vitamin C. After 1 week, fibroblasts were collected and cellular ATP and ADP were determined by UV-
HPLC. Data are represented as nmol of ATP/mg prot (A) and ATP/ADP ratio (B). Results are expressed as mean6 SD of three experiments. P1 = COQ9
mutant; P2 = COQ2 mutant; P3 = COQ2 mutant; P4 = PDSS2 mutant. ***P,0.001 and **P,0.01 compared with untreated control; ##P,0.01 and
###P,0.001 compared with untreated P1; ++P,0.01 and +++P,0.001 compared with untreated P2; V P,0.05 and VV P,0.01 compared with
untreated P4.
doi:10.1371/journal.pone.0011897.g004
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For the 24 h treatment experiments, 75% confluent cells were
grown in RPMI-1640 glucose-free medium with 10% dialyzed fetal
bovine serum, 25 mM HEPES, 1.5 mM Glutamax, 25 mM
galactose, 1 ml fungizone, and 5 ml penicillin-streptomycin for 2
days. Twenty-four hours before the experiments, cells were
incubated in fresh medium supplemented with idebenone
(Santhera Pharmaceuticals, Liestal, Switzerland), CoQ2 (Sigma–
Aldrich Corp., St. Louis, MO, USA), CoQ10 or vitamin C (Sigma-
Aldrich Corp., St. Louis, MO, USA) (5 mM final concentration).
For the 1 week treatment experiments, 60% confluent cells were
incubated for 7 days in RPMI-1640 glucose-free medium with
10% dialyzed fetal bovine serum, 25 mM HEPES, 1.5 mM
Glutamax, 25 mM galactose, 1 ml fungizone, 5 ml penicillin-
streptomycin and one of the following: idebenone, CoQ2, CoQ10,
or vitamin C (5 mM final concentration).
Regular FBS contains 85–245 mg glucose/ml and dialyzed FBS
less than 5 mg glucose/ml. Because our experiments required
glucose-free media supplemented with galactose to force energy
production through oxidative phosphorylation rather than glycol-
ysis [23,49,50], we used 10% dialyzed FBS. This was particularly
important for the 24 h treatment experiments since cells can use
the glucose contained in 10% regular FBS during the first 24–
48 h.
Idebenone, CoQ2, CoQ10, and vitamin C were dissolved in
dialyzed fetal bovine serum prior to addition to culture medium.
All cells culture reagents were obtained from Invitrogen Corp.
(Carlsbad, CA, USA). Patients and control cell lines at passage 7–
10 were grown to replicate every experiment at least 3 times.
Cellular CoQ10 levels
One week after treatment, fibroblast pellets were collected and
washed 4 times with phosphate buffered saline (PBS). After the
fourth wash, no CoQ10 was detected in the PBS supernatant.
CoQ10 from fibroblasts was extracted in a hexane:ethanol mixture
[20]. The lipid component of the extract was separated by HPLC
on a reverse phase SymmetryH C18 3.5 mm, 4.66150 mm column
(Waters), using a mobile phase consisting of methanol, ethanol, 2-
propanol, acetic acid (500:500:15:15) and 50 mM sodium acetate
at a flow rate of 0.9 ml/min. The electrochemical detector
consisted of an ESA Coulochem II with the following setting:
guard cell (upstream of the injector) at +900 mV, conditioning cell
at –600 mV (downstream of the column), followed by the
Figure 5. Superoxide anion production in cells treated with
antioxidant compounds for 24 hours (A) or 1 week (B). Cultured
skin fibroblasts from controls and CoQ10 deficient patients were treated
with 5 mM CoQ10, idebenone, CoQ2, or vitamin C. After 24 h (A) or 1
week (B), fibroblasts were collected and superoxide anion generation
was assessed by MitoSOX staining and quantified by flow cytometry
The Y axis represents the fluorescence intensity of the sample relative
to the fluorescence intensity of the control sample (FP/FC), after
subtracting the background intensity; the X axis represent the sample.
20,000 cells were analyzed in every experiment. Results are expressed as
mean 6 SD of three experiments. P1 =COQ9 mutant; P2 = COQ2
mutant; P3 = COQ2 mutant; P4 = PDSS2 mutant. ***P,0.001 compared
with untreated control; ##P,0.01 and ###P,0.001 compared with
untreated P1; +++P,0.001 compared with untreated P2; ww P,0.01
and www P,0.001 compared with untreated P3.
doi:10.1371/journal.pone.0011897.g005
Figure 6. Dead cells after 24 hours (A) or 1 week of treatment
(B). Cultured skin fibroblasts from controls and CoQ10 deficiency
patients were treated with 5 mM CoQ10, idebenone, CoQ2, or vitamin C.
After 24 h (A) or 1 week (B), fibroblasts were collected and Trypan blue
assays were performed. Results are expressed as mean 6 SD of three
experiments. P1 = COQ9 mutant; P2 = COQ2 mutant; P3 = COQ2
mutant; P4 = PDSS2 mutant. *P,0.05, **P,0.01 and ***P,0.001
compared with untreated control; +P,0.05 and ++P,0.01 compared
with untreated P2; wP,0.05 and www P,0.001 compared with
untreated P3.
doi:10.1371/journal.pone.0011897.g006
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analytical cell at +500 mV. CoQ10 concentration was estimated by
comparison of the peak area with those of standard solutions of
known concentration [20].
Mitochondrial bioenergetics assessment
Fibroblasts cultured under glucose-free media supplemented
with galactose possess ATP and ADP pools that are predominantly
dependent on the oxidative phosphorylation [23,49]; therefore,
using these culture conditions, ATP levels and ATP/ADP ratio are
reliable markers of oxidative phosphorylation and correlate with
the rates of ATP synthesis in CoQ10 deficient cells, as reported
[23]. To determine the adenine nucleotides levels, cells were
grown in 15-cm-diameter plates to 90% confluency and the
adherent cells were collected in ice-cold PBS using a scraper. After
centrifugation at 3,000 g for 3 min at 4uC, pellets were suspended
in 200 ml of ice-cold 0.5 M perchloric acid, vortexed for 30 s, and
centrifuged at 11,000 g for 10 min at 4uC. Pellets were stored at
280uC for protein measurement. Adenine nucleotides were
measured in the supernatants injected into an Alliance HPLC
(Waters Corporation, Milford, MA, USA) with an Alltima C18
NUC reverse-phase column (Alltech Associates, Deerfield, IL,
USA) [23]. Adenine nucleotide levels were expressed in nmol/mg
protein. Because of poor growth of P3 cells, the 1 week
experiments were performed only in P1, P2 and P4 fibroblasts.
Oxidative stress analyses
Previously, we demonstrated that oxidative stress can be
detected by MitoSOX Red assay, lipid peroxidation assay, and
carbonyl groups detection in CoQ10 deficient cells due to COQ2
mutation [23]; and results of the three assays were highly
concordant [23]. Here, to evaluate the effect of the proposed
treatments in those and others CoQ10 deficient cells, we estimated
mitochondrial matrix oxidant levels in control and mutant
fibroblasts using MitoSOX Red, a fluorochrome specific for
mitochondrial matrix reactive oxygen species (ROS) burden
(Molecular Probes, Invitrogen Corp., Carlsbad, CA, USA) as
described [23,51]. Approximately 16106 adherent cells (90%
confluence) were trypsinized, incubated with 5 mM MitoSox for
20 min at 37uC in the dark, washed twice with PBS and re-
suspended in 500 ml of PBS. Cytofluorometric analysis was
performed using a FACSCalibur cell analyzer equipped with a
488 nm At-kt laser and fluorescence was measured using the FL2
channel. Fluorescence was background subtracted and normalized
to the signal of control values (FP/FC). Data were acquired using
Cell Pro Quest and analyzed using Flowjo software (Becton
Dickinson, NJ, USA). Before to start with the set of experiments
for the cytofluorometric analysis, the MitoSOX staining was
evaluated and monitored by fluorescence microscopy (IX70
inverted system microscope, Olympus, Tokyo, Japan). Addition-
ally, a control cell line treated with 0.5 mM antimycin A for 15 h
before the MitoSOX staining was used as a positive control for
increased ROS production [23].
Oxidative stress-induced death cells studies
Measurement of cell viability was performed with the Trypan
blue exclusion method. Numbers of living and dead adherent cells
were determined by light microscopy using a hemocytometer. We
also determined the proportion dead non-adherent P2 cells.
Healthy nuclei from viable cells appeared round and phase bright,
whereas nuclei from dead or dying cells appeared blue and
irregularly shaped. All cells were counted and results were
expressed as percentage of dead cells relative to total cells [52].
Statistical analysis
Control data are expressed as mean6 SD of 5 different samples
in triplicate experiments. Patients’ data are expressed as mean 6
SD of triplicate experiments. One-way analysis of variance
(ANOVA) followed by Student-Newman-Keuls multiple compar-
isons test was used. A P value of less than 0.05 was considered
statistically significant.
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